Fig 1: GNAQ expression is not correlated with DFS or OS in GC patients. (A) Patients with GNAQ overexpression (red) in GC surgical specimens exhibited no difference in DFS compared with patients without GNAQ expression (blue) (median DFS, 42.288 vs. 40.308 months; p=0.496). (B) Patients with GNAQ overexpression (red) in GC surgical specimens exhibited no difference in OS compared with patients without overexpression (blue) (median OS, 45.675 vs. 44.076 months; p=0.430). (C) No significant difference was observed in the DFS of elder (=60 years) GC patients with GNAQ-positive and -negative tumors (p=0.883). (D) No significant difference was observed in the OS of elder (=60 years) GC patients with GNAQ-positive and -negative tumors (p=0.954). (E) No significant difference was observed in the DFS of younger (<60 years) GC patients with GNAQ-positive and -negative tumors (p=0.295). (F) No significant difference was observed in the OS of younger (<60 years) GC patients with GNAQ-positive and -negative tumors (p=0.287). (G) No significant difference was observed in the DFS of GC patients with intermediate histological differentiation in the positive GNAQ expression and negative groups (p=0.737). (H) No significant difference was observed in the OS of GC patients with intermediate histological differentiation in the positive GNAQ expression and negative groups (p=0.516). (I) No marked difference was displayed in the DFS of GC patients with poor histological differentiation in the GNAQ-positive and -negative group (p=0.931). (J) No marked difference was displayed in the OS of GC patients with poor histological differentiation in the GNAQ-positive and -negative group (p=0.756). (K) No significant difference was observed in the DFS of GC patients who received adjuvant therapy in the GNAQ-positive and -negative group (p=0.607). (L) No significant difference was observed in the OS of GC patients who received adjuvant therapy in the GNAQ-positive and-negative group (p=0.600). (M) No significant difference was observed in the DFS of GC patients who did not receive adjuvant therapy in GNAQ-positive and -negative group (p=0.692). (N) No significant difference was observed in the OS of GC patients who did not receive adjuvant therapy in GNAQ-positive and -negative group (p=0.767). GNAQ, G protein subunit a q; GC, gastric cancer; DFS, disease-free survival; OS, overall survival.